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Background-—Intravascular imaging can facilitate chronic total occlusion (CTO) percutaneous coronary intervention.
Methods and Results-—We examined the frequency of use and outcomes of intravascular imaging among 619 CTO percutaneous
coronary interventions performed between 2012 and 2015 at 7 US centers. Mean age was 65.410 years and 85% of the patients
were men. Intravascular imaging was used in 38%: intravascular ultrasound in 36%, optical coherence tomography in 3%, and both
in 1.45%. Intravascular imaging was used for stent sizing (26.3%), stent optimization (38.0%), and CTO crossing (35.7%, antegrade
in 27.9%, and retrograde in 7.8%). Intravascular imaging to facilitate crossing was used more frequently in lesions with proximal cap
ambiguity (49% versus 26%, P<0.0001) and with retrograde as compared with antegrade-only cases (67% versus 31%, P<0.0001).
Despite higher complexity (Japanese CTO score: 2.861.19 versus 2.431.19, P=0.001), cases in which imaging was used for
crossing had similar technical and procedural success (92.8% versus 89.6%, P=0.302 and 90.1% versus 88.3%, P=0.588,
respectively) and similar incidence of major cardiac adverse events (2.7% versus 3.2%, P=0.772). Use of intravascular imaging was
associated with longer procedure (192 minutes [interquartile range 130, 255] versus 131 minutes [90, 192], P<0.0001) and
ﬂuoroscopy (71 minutes [44, 93] versus 39 minutes [25, 69], P<0.0001) time.
Conclusions-—Intravascular imaging is frequently performed during CTO percutaneous coronary intervention both for crossing and
for stent selection/optimization. Despite its use in more complex lesion subsets, intravascular imaging was associated with similar
rates of technical and procedural success for CTO percutaneous coronary intervention.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT02061436. ( J Am Heart Assoc. 2016;5:
e003890 doi: 10.1161/JAHA.116.003890)
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U se of intravascular ultrasound (IVUS) for stent optimiza-tion during chronic total occlusion percutaneous
coronary intervention (CTO PCI) has been shown to improve
long-term outcomes,1–3 yet its impact on crossing has
received limited study.1–9 Intravascular imaging can help
resolve proximal cap ambiguity by identifying the position of
the main branch10 and clarifying guidewire position during
both antegrade and retrograde CTO crossing attempts.11
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IVUS can determine optimal balloon sizing for the reverse
controlled antegrade and retrograde tracking and dissection
(reverse CART) technique.11,12 Moreover, intravascular imag-
ing can facilitate sizing of balloons and stents and optimize
stent expansion and stent strut apposition.13 We examined a
large multicenter contemporary CTO PCI registry to determine
the frequency of intravascular imaging use during CTO PCI
and the associated procedural outcomes.
Methods
Patient Population
We analyzed the frequency of use and outcomes of intravas-
cular imaging among 619 chronic CTO PCIs performed
between 2012 and 2015 at 7 US centers: Appleton Cardiol-
ogy, Appleton Wisconsin; Henry Ford Hospital, Detroit,
Michigan; Massachusetts General Hospital, Boston, Mas-
sachusetts; Medical Center of the Rockies, Loveland, Color-
ado; St. Luke’s Health System’s Mid-America Heart Institute,
Kansas City, Missouri; VA North Texas Health Care System,
Dallas, Texas; and VA San Diego Healthcare System, San
Diego, California.
Enrollment was performed during only part of the study
period in some centers due to participation in other studies.
Data collection was performed both prospectively and retro-
spectively and was recorded in a dedicated online database
(PROGRESS CTO: Prospective Global Registry for the Study of
Chronic Total Occlusion Intervention, Clinicaltrials.gov Identi-
ﬁer: NCT02061436).14–24 The study was approved by the
institutional review board of each site and a waiver of
informed consent was obtained.
Deﬁnitions
Coronary CTOs were deﬁned as coronary lesions with
Thrombolysis In Myocardial Infarction grade 0 ﬂow of at least
3-month duration.25 Estimation of the occlusion duration was
based on ﬁrst onset of anginal symptoms, prior history of
myocardial infarction in the target vessel territory, or
comparison with a prior angiogram. Calciﬁcation was
assessed by angiography as mild (spots), moderate (involving
≤50% of the reference lesion diameter), and severe (involving
>50% of the reference lesion diameter). Moderate proximal
vessel tortuosity was deﬁned as the presence of at least 2
bends >70° or 1 bend >90° and severe tortuosity as 2 bends
>90° or 1 bend >120° in the CTO vessel. The Japanese
Chronic Total Occlusion score was calculated as described by
Morino et al.26 The Progress CTO score was calculated as
described by Christopoulos et al.22 Technical success was
deﬁned as successful CTO revascularization with achievement
of <30% residual diameter stenosis within the treated
segment and restoration of Thrombolysis In Myocardial
Infarction grade 3 antegrade ﬂow. Procedural success was
deﬁned as achievement of technical success with no in-
hospital major adverse cardiac events (MACE). In-hospital
MACE included any of the following adverse events prior to
hospital discharge: death, myocardial infarction, urgent repeat
target vessel revascularization with either PCI or coronary
artery bypass graft surgery, tamponade requiring either
pericardiocentesis or surgery, and stroke. Myocardial infarc-
tion was deﬁned using the Third Universal Deﬁnition of
Myocardial Infarction.27
Statistical Analysis
The primary comparison of the study was between procedures
in which intravascular imaging (IVUS and/or optical coher-
ence tomography [OCT]) was used versus those in which it
was not used for crossing the occlusion (Figure 1). In a
secondary analysis of cases that were successfully crossed
with a guidewire, a comparison was made between use versus
no use of intravascular imaging for stent sizing/optimization.
Continuous variables were presented as meanSD or
median (interquartile range) and were compared using the t
test, or Wilcoxon rank-sum test, as appropriate. Categorical
data were reported as frequencies or percentages and
compared using the v2 test or Fisher’s exact test, as
appropriate. The baseline clinical characteristics and the
procedural outcomes were analyzed among the patients (606
patients), while the angiographic characteristics were ana-
lyzed among procedures (619 procedures). All statistical
analyses were performed with JMP 11.0 (SAS Institute,
Cary, NC). Two-sided P<0.05 were considered statistically
signiﬁcant.
Results
Baseline Patient and Procedural Characteristics
A total of 619 CTO PCI procedures performed in 606 patients
were included in the present analysis. The baseline patient
and angiographic characteristics of the study population are
summarized in Table 1. Mean age was 65.410 years and
85% of the patients were men with high prevalence of
diabetes (50%), dyslipidemia (92%), and hypertension (88%).
Approximately one third had congestive heart failure (33%) or
prior coronary artery bypass graft surgery (32%).
Intravascular imaging was used in 38% of the procedures,
as follows: IVUS in 36%, OCT in 3%, and both in 1.45%. The
indications for intravascular imaging were to facilitate CTO
crossing (overall 35.7%, antegrade in 27.9%, and retrograde in
7.8%) and stent sizing (26.3%) or optimization (38.0%)
(Figure 2). Wide variability was observed in the frequency of
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intravascular imaging use among various centers (0–58%,
Figure 3).
Intravascular Imaging for Crossing
The baseline clinical and angiographic characteristics of
patients who did and those who did not undergo intravas-
cular imaging for crossing were similar (Tables 1 and 2). The
most common CTO PCI target vessel was the right coronary
artery (52%), followed by the left anterior descending artery
(26%), and the left circumﬂex (22%). Moderate to severe
calciﬁcation and moderate to severe tortuosity were present
in 53% and 42%, respectively. Procedural outcomes are
summarized in Table 3. Overall technical and procedural
rates were 90.1% and 88.6%, respectively. Antegrade wiring
was the successful crossing strategy in 48% of the cases,
antegrade dissection and re-entry in 23%, and the retrograde
approach in 23%.
Intravascular imaging for crossing was used more com-
monly in lesions with proximal cap ambiguity (49% versus
26%, P<0.0001), side branch at the proximal cap (61% versus
47%, P=0.035), longer occlusion length (30 mm [interquartile
range: 22, 50] versus 28 mm [15, 44], P=0.009), and higher
Japanese Chronic Total Occlusion (2.861.19 versus
2.431.19, P=0.001) and Progress CTO (1.641.00 versus
1.181.02, P<0.0001) score. Cases in which intravascular
imaging was used for crossing were more likely to succeed
using the retrograde approach or antegrade dissection and
reentry (47% versus 17% and 25% versus 23%), as compared
with antegrade wiring (23% versus 53%, P<0.0001).
Procedural outcomes are summarized in Table 3 and
Figure 4. Technical and procedural success were similar in
cases in which intravascular imaging was used for crossing
(92.8% versus 89.6%, P=0.302 and 90.1% versus 88.3%,
P=0.588, respectively), whereas the incidence of MACE was
similarly low in both groups (2.7% versus 3.2%, P=0.772).
Success and complication rates were similar among centers
with high versus low intravascular imaging use (data not
shown). There was no signiﬁcant difference in the incidence of
death, myocardial infarction, repeated PCI, stroke, and
pericardiocentesis. Mean procedure duration was signiﬁcantly
longer among procedures in which intravascular imaging was
used for crossing (192 minutes [130, 255] versus 131 min-
utes [90, 192], P<0.0001), as was median ﬂuoroscopy time
(71 minutes [44, 93] versus 39 minutes [25, 69], P<0.0001),
mean air kerma radiation dose (4.98 Gray [3.11, 6.04] versus
3.42 Gray [2.09, 5.09], P<0.0001), and median contrast
volume (310 mL [240, 400] versus 270 mL [200, 360],
P=0.004) as compared with cases in which intravascular
imaging was not used.
Figure 1. Flow chart of the study. CTO indicates chronic total occlusion; PCI, percutaneous coronary
intervention.
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Intravascular Imaging for Stent Sizing and/or
Optimization
Among CTOs successfully crossed with a guidewire, cases in
which imaging was used for stent sizing and optimization were
more complex, as reﬂected by higher Japanese Chronic Total
Occlusion (2.651.17 versus 2.381.22, P=0.013) and
Progress CTO (1.391.09 versus 1.190.98, P=0.035)
scores (Tables 4 and 5). They were also more likely to have
moderate/severe calciﬁcation (63% versus 47%, P=0.001),
longer occlusion length (30 mm [20, 50] versus 28 mm [15,
40], P=0.030) or be due to in-stent restenosis (23% versus
14%, P=0.015) and required longer procedure (162 minutes
[113, 216] versus 133 minutes [91, 201], P=0.001) and
ﬂuoroscopy (52 minutes [33, 81] versus 40 minutes [26, 73],
P=0.014) time with a trend for higher air kerma radiation dose
(3.90 Gray [2.48, 5.46] versus 3.48 Gray [2.13, 5.34],
P=0.249) and contrast volume (300 mL [228, 368] versus
277 mL [200, 370], P=0.106). Use of intravascular imaging
was associated with similar technical (97.7% versus 97.5%,
P=0.854) and procedural (97.1% versus 95.4%, P=0.347)
success rates and similarly low MACE rates (2.3% versus
3.1%, P=0.622) (Figure 5). There was a trend toward larger
number of stents in procedures where intravascular imaging
was used for stent sizing/and/or optimization (2.71.3
versus 2.51.2, P=0.07).
Discussion
The main ﬁndings of our study are that intravascular imaging
is frequently performed during CTO PCI both for crossing and
for stent selection/optimization. Intravascular imaging was
used in more complex occlusions and was associated with
similarly high success rates, but longer procedure time and
higher radiation dose.
Frequency of Intravascular Imaging Use in CTO
PCI
In our study, intravascular imaging was used in 38% of CTO
PCI cases, which is similar to 39% utilization in the Multicenter
Korean CTO Registry.1 Okamura et al reported use of IVUS in
47.5% of patients in their study about complications during
retrograde approach in the Japanese Multicenter CTO Registry
IVUS.28 In contrast, in the European Registry of Chronic Total
Occlusion, IVUS use was signiﬁcantly lower (2.9% overall29
and 9.2% in retrograde cases30), suggesting that imaging use
may be low even among experienced operators and centers.
Habara et al31 compared CTO PCI outcomes according to
operator experience: when using the antegrade approach
after retrograde failure, the success rate of IVUS-guided
techniques was signiﬁcantly higher in higher-volume centers
than lower-volume centers (13.3% versus 3.3%; P=0.018).
Therefore, IVUS guidance for antegrade crossing requires high
operator skill and experience.32 Moreover, the cost of
catheters and the additional time required for obtaining and
interpreting the images can affect the use of intravascular
imaging and may explain the wide variability in its use for CTO
(and non-CTO) PCI.
Selection of Intravascular Imaging Modality for
CTO PCI
IVUS was the intravascular imaging modality used in most
CTO PCIs, and in contrast to OCT, does not require ﬂushing of
Table 1. Baseline Clinical Characteristics of the Study
Patients, Classiﬁed According to Whether Intravascular
Imaging Was Used to Guide CTO Crossing or Not
Variable
Overall
Imaging
for
Crossing
No Imaging
or Imaging
for Stent
Optimization
P-Value(n=606) (n=111) (n=495)
Age, y* 65.410 6510 6610 0.466
Men 85% 91% 84% 0.066
BMI, kg/m2* 30.66 31.77 30.46 0.058
Diabetes mellitus 50% 58% 49% 0.069
Hypertension 88% 88% 88% 0.908
Dyslipidemia 92% 94% 92% 0.631
Smoking
(current)
23% 77% 77% 0.908
LVEF (%)* 5115 4815 5115 0.056
Family history of
CAD
24% 24% 24% 0.897
Congestive heart
failure
33% 37% 32% 0.29
Prior myocardial
infarction
45% 46% 44% 0.793
Prior CABG 32% 41% 30% 0.024
Prior CVD 11% 8% 12% 0.331
Prior PVD 15% 12% 15% 0.403
Baseline
creatinine,
mg/dL†
1.0
(0.8, 1.2)
1.0
(0.9, 1.3)
1.0
(0.8, 1.2)
0.615
Imaging for crossing: cases in which intravascular imaging was used for crossing the
chronic total occlusion. No imaging or imaging for stent optimization: cases in which
intravascular imaging was not used or cases in which intravascular imaging was used for
stent optimization. BMI indicates body mass index; CABG, coronary artery bypass
grafting; CAD, coronary artery disease; CTO, chronic total occlusion; CVD,
cerebrovascular disease; LVEF, left ventricular ejection fraction; PCI, percutaneous
coronary intervention; PVD, peripheral vascular disease.
*MeanSD.
†Median (interquartile range).
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the blood column within the arterial lumen and has higher
penetration depth. OCT performed before stenting could also
cause subintimal hematoma due to the need for contrast
administration for image acquisition. OCT, however, offers
superior resolution compared to IVUS and has been used in
CTO PCI to determine guidewire position and stent optimiza-
tion after deployment. The ALSTER OCT-CTO (AskLepios ST.
GEoRg’s Hospital-Optical Coherence Tomography for follow-
Figure 2. Use of intravascular imaging during chronic total occlusion percutaneous coronary intervention.
CART indicates controlled antegrade and retrograde tracking and dissection.
Figure 3. Frequency of intravascular imaging use at the study participating centers. The absolute number
of the cases with intravascular imaging use is listed in parentheses.
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up of Chronic Total Occlusions) registry reported a signif-
icantly higher rate of uncovered and malapposed stent struts
in CTOs as compared to nonocclusive lesions.33 These
ﬁndings may favor prolonged administration of dual antiplate-
let therapy, in an attempt to reduce the risk of stent
thrombosis.34
Solid-state, phased-array catheters (Eagle-Eye, Volcano)
are preferred over rotational IVUS systems, because the
imaging transducer is closer to the tip of the IVUS catheter. A
short-tip solid-state IVUS catheter (Eagle Eye Short Tip,
Volcano) is advantageous for imaging in CTO PCI, as it
minimizes the extent of distal advancement required for distal
imaging and may be more deliverable.10
Imaging for CTO Crossing
Intravascular imaging can assist CTO crossing by (1) identifying
the proximal cap in cases with proximal cap ambiguity (for
example, by imaging through a side branch adjacent to the
occlusion)4; (2) conﬁrming whether the antegrade guidewire
Table 2. Angiographic Characteristics Classiﬁed According to Whether Intravascular Imaging was Used to Guide CTO Crossing or
Not
Variable
Overall
Imaging for
Crossing
No Imaging or Imaging
for Stent Optimization
P-Value(n=619) (n=111) (n=508)
CTO target vessel 0.861
RCA 52% 51% 52%
LAD 26% 28% 26%
LCX 22% 21% 22%
Successful crossing strategy <0.0001
Antegrade wiring 48% 23% 53%
Retrograde 23% 47% 17%
Antegrade dissection and re-entry 23% 25% 23%
None 6% 5% 7%
First crossing strategy 0.889
Antegrade wiring 78% 78% 78%
Retrograde 14% 15% 14%
Antegrade dissection and re-entry 8% 6% 8%
Retrograde crossing attempt 37% 67% 31% <0.0001
J-CTO score* 2.511.20 2.861.19 2.431.19 0.001
P-CTO score* 1.371.01 1.641.00 1.181.02 <0.0001
Calcification (moderate/severe) 53% 60% 51% 0.103
Tortuosity (moderate/severe) 42% 48% 40% 0.126
Proximal cap ambiguity 31% 49% 26% <0.0001
In-stent restenosis 17% 20% 16% 0.334
Prior failure to open CTO 16% 21% 15% 0.147
Interventional collaterals 53% 52% 53% 0.794
Side branch at the proximal cap 50% 61% 47% 0.009
Blunt/no stump, % 57% 68% 55% 0.009
Vessel diameter, mm† 2.6 (2.5, 3.0) 2.5 (2.5, 3.0) 2.7 (2.5, 3.0) 0.684
Occlusion length, mm† 30 (19, 45) 30 (22, 50) 30 (18, 40) 0.093
Number of stents used 2.531.2 2.781.4 2.481.19 0.047
Imaging for crossing: cases in which intravascular imaging was used for crossing the chronic total occlusion. No imaging or imaging for stent optimization: cases in which intravascular
imaging was not used or cases in which intravascular imaging was used for stent optimization. CTO indicates chronic total occlusion; J-CTO score, Japanese chronic total occlusion score;
LAD, left anterior descending artery; LCX, left circumﬂex artery; P-CTO score, Progress chronic total occlusion score; RCA, right coronary artery.
*MeanSD.
†Median (interquartile range).
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has engaged the occlusion and navigating the antegrade
guidewire to the true lumen in case of dissection5,35; (3)
conﬁrming that the retrograde guidewire has entered the
proximal true lumen before externalization; and (4) determining
the appropriate balloon size for the CART and reverse CART
techniques.10,11 Moreover, use of IVUS could assist re-entry
into the distal true lumen after subintimal crossing35 and
reduce the need for ﬂuoroscopy and contrast injection.5 In our
study, 3 characteristics of CTOs were associated with
IVUS utilization during crossing: side branch at proximal cap
Table 3. Procedural Outcomes of the Study Patients, Classiﬁed According to Whether Intravascular Imaging was Used to Guide
CTO Crossing or Not
Variable Overall
Imaging for
Crossing
No Imaging or Imaging
for Stent Optimization P-Value
Technical success 90.1% 92.8% 89.6% 0.302
Procedural success 88.6% 90.1% 88.3% 0.588
Procedural time, minute* 142 (96, 210) 192 (130, 255) 131 (90, 192) <0.0001
Fluoroscopy time, minute* 45 (27, 75) 71 (44, 93) 39 (25, 69) <0.0001
Air kerma radiation dose (Gray)* 3.59 (2.27, 5.40) 4.98 (3.11, 6.04) 3.42 (2.09, 5.09) <0.0001
Contrast volume* 280 (205, 367) 310 (240, 400) 270 (200, 360) 0.004
MACE 3.1% 2.7% 3.2% 0.772
Death 0.5% 0.0% 0.6% 0.411
Acute Q wave MI 0% 0% 0.0% —
Acute MI 1.3% 1.8% 1.2% 0.623
Re-PCI 0.3% 0.0% 0.4% 0.502
Stroke 0.4% 0.0% 0.6% 0.411
Emergency CABG 0% 0% 0.0% —
Pericardiocentesis 0.9% 0.9% 1.0% 0.916
Imaging for crossing: cases in which intravascular imaging was used for crossing the chronic total occlusion; No imaging or imaging for stent optimization: cases in which intravascular
imaging was not used or cases in which intravascular imaging was used for stent optimization. CABG indicates coronary artery bypass grafting; CTO, chronic total occlusion; MACE, major
adverse cardiac events; MI, myocardial infarction; PCI, percutaneous coronary intervention.
*Median (interquartile range).
Figure 4. Technical, procedural success and MACE among study procedures classiﬁed according to use
of intravascular imaging for crossing. MACE indicates major cardiac adverse event.
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(61% versus 47%, P=0.009), proximal cap ambiguity (49%
versus 26%, P<0.001), and blunt/no stump (68% versus 55%,
0.009).
Park et al reported that the IVUS-guided wiring technique
was useful and safe for antegrade recanalization of 31
stumpless CTOs (Table 6). The IVUS catheter was advanced
into the side branch to identify the CTO entry point, while
another stiffer guidewire was directed under IVUS guidance to
the occlusion entry point and penetrated the proximal cap. In
case of subintimal position of the guidewire, IVUS was also
used to redirect the wire into the true lumen. However, this
technique has 2 potential limitations: ﬁrst, IVUS cannot
provide information on the course of the vessel distal to the
occlusion (dual injection can be used to visualize the entire
course of the vessel distal to the occlusion); second, IVUS-
guided wiring cannot be applied in cases without appropriate
side branches (for example, with smaller vessel diameter than
the IVUS catheters).4
IVUS may be particularly useful for the retrograde
approach to CTO crossing, as retrograde cases are often
more complex than antegrade-only cases due to difﬁculties
crossing the collateral and/or crossing the occlusion and
Table 4. Angiographic Characteristics Classiﬁed According to Whether or Not Intravascular Imaging Technique Was Used for Stent
Optimization
Variable
Overall
Imaging for Stent
Optimization
No Imaging or Imaging
for Crossing Only
P-Value(n=568) (n=175) (n=393)
CTO target vessel 0.137
RCA 51% 49% 52%
LAD 27% 32% 25%
LCX 22% 19% 23%
Successful crossing strategy 0.001
Antegrade wiring 51% 42% 55%
Retrograde 24% 27% 23%
Antegrade dissection and re-entry 25% 31% 22%
First crossing strategy 0.321
Antegrade wiring 78% 77% 79%
Retrograde 14% 13% 14%
Antegrade dissection and re-entry 8% 10% 7%
Retrograde crossing attempt 36% 45% 32% 0.003
J-CTO score* 2.471.21 2.651.17 2.381.22 0.013
Progress CTO score* 1.251.02 1.391.09 1.190.98 0.035
Calcification (moderate/severe) 52% 63% 47% 0.001
Tortuosity (moderate/severe) 41% 42% 40% 0.742
Proximal cap ambiguity 30% 34% 28% 0.155
In-stent restenosis 17% 23% 14% 0.015
Prior failure to open CTO 16% 18% 15% 0.429
Interventional Collaterals 53% 52% 54% 0.648
Side branch at the proximal cap 49% 50% 48% 0.753
Blunt/no stump 55% 50% 57% 0.123
Vessel diameter, mm† 2.5 (2.5, 3.0) 2.8 (2.5, 3) 2.5 (2.5, 3) 0.257
Occlusion length, mm† 30 (18, 45) 30 (20, 50) 28 (15, 40) 0.03
Number of stents used 2.51.2 2.71.3 2.51.2 0.076
Imaging for stent optimization: cases in which intravascular imaging was used for stent optimization. No imaging or imaging for crossing only: cases in which intravascular imaging was not
used or cases in which intravascular imaging was used only for crossing the chronic total occlusion. CTO indicates chronic total occlusion; J-CTO score, Japanese chronic total occlusion
score; LAD, left anterior descending artery; LCX, left circumﬂex artery; P-CTO score, Progress chronic total occlusion score; RCA, right coronary artery.
*MeanSD.
†Median (interquartile range).
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externalizing the guidewire. Indeed, IVUS was used in 67% of
retrograde versus 31% of antegrade-only cases in our study
(P<0.0001). IVUS can clarify the location of guidewires and
guide balloon size selection when performing reverse CART.
Dai et al showed that the IVUS-guided reverse CART approach
is efﬁcient and safe for revascularization of complex CTOs.
Table 5. Procedural Outcomes of the Study Patients, Classiﬁed According to Whether Intravascular Imaging was Used for Stent
Optimization or Not
Variable Overall
Imaging for Stent
Optimization
No Imaging or Imaging
for Crossing Only P-Value
Technical success 97.5% 97.7% 97.5% 0.854
Procedural success 95.9% 97.1% 95.4% 0.347
Procedural time, min* 143 (97, 205) 162 (113, 216) 133 (91, 201) 0.001
Fluoroscopy time, min* 44 (27, 75) 52 (33, 81) 40 (26, 73) 0.014
Air kerma radiation dose (Gray)* 3.60 (2.24, 5.37) 3.90 (2.48, 5.46) 3.48 (2.13, 5.34) 0.249
Contrast volume* 282 (205, 369) 300 (228, 368) 277 (200, 370) 0.106
MACE 2.9% 2.3% 3.1% 0.622
Death 0.4% 0.0% 0.5% 0.347
Acute Q wave MI 0% 0% 0.0%
Acute MI 1.3% 0.6% 1.6% 0.346
Re-PCI 0.4% 0.0% 0.5% 0.347
Stroke 0.7% 0.6% 0.8% 0.808
Emergency CABG 0% 0% 0.0%
Pericardiocentesis 0.7% 1.2% 0.5% 0.398
Imaging for stent optimization: cases in which intravascular imaging was used for stent optimization. No imaging or imaging for crossing only: cases in which intravascular imaging was not
used or cases in which intravascular imaging was used only for crossing the chronic total occlusion. CABG, coronary artery bypass graft; MACE, major adverse cardiac events; MI,
myocardial infarction; PCI, percutaneous coronary intervention.
*Median (interquartile range).
Figure 5. Technical, procedural success and major cardiac adverse events according to purpose of
intravascular imaging techniques. IMG indicates imaging; MACE, major cardiac adverse events.
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They overlapped an antegrade and a retrograde guidewire
within the occlusion and inﬂated a small balloon (1.2–
1.5 mm) to create an antegrade subintimal or intimal
dissection. The IVUS catheter was then advanced into the
dissection plane to guide crossing of the occlusion.11
Imaging for Stent Optimization
Intravascular imaging can assist with optimizing stent diam-
eter and length selection, and further ensure that optimal
expansion has occurred.10 Two randomized-controlled trials
have compared IVUS guidance versus angiographic guidance
for stent optimization after CTO PCI. Kim et al randomized
402 patients to IVUS guidance versus angiographic guidance
and found that IVUS guidance reduced the subsequent
incidence of MACE.3 Similarly, Tian et al in the AIR-CTO
(Angiographic and clinical comparisons of intravascular ultra-
sound- versus angiography-guided drug-eluting stent implan-
tation for patients with Chronic Total Occlusion lesions) study
randomized 230 patients to IVUS or angiographic guidance
and found that IVUS guidance was associated with lower in-
stent late lumen loss at 1-year angiographic and IVUS follow-
up, leading to less frequent restenosis and lower rates of
stent thrombosis.2 These ﬁndings are in agreement with the
ﬁndings of the IVUS-XPL (The Impact of Intravascular
Ultrasound Guidance on Outcomes of Xience Prime Stents
in Long Lesions) study that randomized 1400 patients to
undergo IVUS-guided or angiography-guided everolimus-elut-
ing stent implantation in non-CTO long lesions and resulted in
a signiﬁcantly lower rate of 12-month MACE, primarily driven
by lower risk for target lesion revascularization.36 Use of
intravascular imaging (either IVUS or OCT) can help identify
and treat stent underexpansion, which is an important risk
factor for both restenosis6 and stent thrombosis. Use of
intravascular imaging may be of particular importance in long
and calciﬁed CTOs. In our study we observed a trend toward a
higher number of stents in procedures guided by IVUS. This
could be related to higher lesion complexity among imaged
Table 6. Summary of Published Reports of Intravascular Ultrasound Use in CTO PCI
Author Year
No. of
Patients
No. of
Lesions
Imaging
Frequency Comments
Intravascular imaging for crossing
Antegrade
crossing
Park et al4 2011 31 32 100% IVUS-guided wiring is technically feasible and safe for recanalization of
stumpless CTO lesions
Ito et al35 2004 2 2 100% Case report: (1) IVUS advanced into a side branch to identify the entry
point of the major branch (2) IVUS-guided penetration of the
guidewire from the false lumen to the true lumen after dissection
Matsubara et al5 2004 2 2 100% Case report: (1) IVUS catheter in the subintima was used to guide the
wire into the true lumen. (2) The orifice of the LAD was identified by
imaging with IVUS in a diagonal branch
Retrograde
crossing
Dai et al11 2013 49 49 100% IVUS-guided reverse CART approach is efficient and safe for
revascularization of complex CTOs
Intravascular imaging for stent optimization
Retrospective
studies
Kang et al6 2015 126 126 100% Among patients in whom IVUS was used post CTO PCI, post CTO-PCI
angiographic minimum luminal diameter ≤2.4 mm and stent
expansion ratio ≤70% as assessed by IVUS were both independent
predictors of in-stent restenosis
Hong et al1 2014 534 534 50% IVUS was used in 39% of CTO PCI and was associated with lower risk
for stent thrombosis and a trend for lower incidence of myocardial
infarction as compared with angiography-guided CTO PCI
Tsujita et al32 2009 48 48 100% Compared antegrade and retrograde approaches with IVUS after
crossing; IVUS can be a useful tool for the detection of procedure-
related vessel damage and subintimal wire tracking
Prospective
randomized-
controlled
clinical trials
Kim et al3 2015 402 402 50% Randomized-controlled trial of IVUS guidance in CTO PCI demonstrating
lower 12-month incidence of MACE in the IVUS-guidance group
Tian et al2 2015 230 230 50% Randomized-controlled trial of IVUS guidance in CTO PCI demonstrating
that IVUS guidance was associated with less late lumen loss and a
lower incidence of 12-month in-stent restenosis
CART indicates controlled antegrade and retrograde tracking and dissection; CTO, chronic total occlusion; IVUS, intravascular ultrasound; LAD, left anterior descending artery; MACE, major
adverse cardiac events; PCI, percutaneous coronary intervention.
DOI: 10.1161/JAHA.116.003890 Journal of the American Heart Association 10
Intravascular Imaging in CTO PCI Karacsonyi et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on September 27, 2019
lesions, but could also indicate increased detection of
dissection ﬂaps, gaps between stents, or untreated residual
coronary disease that might have not been apparent during
diagnostic angiography.
Intravascular Imaging and Contrast Use
Mariani et al in the MOZART (Minimizing cOntrast utilization
With IVUS Guidance in CoRonary angioplasTy) trial found that
IVUS as a primary imaging tool to guide PCI was safe and
markedly reduced the volume of iodine contrast as compared
with angiography-guided PCI.37 Dai et al suggested that the
IVUS-guided reverse CART technique could reduce the
contrast volume.11 However, in our study contrast volume
was higher among cases in which intravascular imaging was
used for crossing, likely reﬂecting the higher complexity of
such cases.
Study Limitations
Our study has potential limitations. First, PROGRESS CTO is
an observational registry without adjudication of clinical
events by an independent event committee. Second, quanti-
tative coronary angiographic analysis was not performed and
therefore assessment of angiographic characteristics was
subject to operator-related bias. Third, procedures were
performed by experienced operators in CTO PCI, limiting
extrapolation of the study results to less experienced centers
and operators. Fourth, use of intravascular imaging was
performed at the discretion of the operator, with high
variability between centers. Fifth, few patients (n=13) had
more than 1 CTO PCI.
Conclusion
In summary, intravascular imaging is frequently performed
during CTO PCI both for crossing and for stent selection/
optimization. Even though intravascular imaging was used in
more complex lesions, it was associated with similar rates of
technical and procedural success, but higher use of radiation
and longer procedure time.
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